Factors Associated With Circulating Sex Hormones in Men : Individual Participant Data Meta-analyses.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
09 2023
Historique:
medline: 20 9 2023
pubmed: 28 8 2023
entrez: 28 8 2023
Statut: ppublish

Résumé

Various factors modulate circulating testosterone in men, affecting interpretation of testosterone measurements. To clarify factors associated with variations in sex hormone concentrations. Systematic literature searches (to July 2019). Prospective cohort studies of community-dwelling men with total testosterone measured using mass spectrometry. Individual participant data (IPD) (9 studies; Two-stage random-effects IPD meta-analyses found a nonlinear association of testosterone with age, with negligible change among men aged 17 to 70 years (change per SD increase about the midpoint, -0.27 nmol/L [-7.8 ng/dL] [CI, -0.71 to 0.18 nmol/L {-20.5 to 5.2 ng/dL}]) and decreasing testosterone levels with age for men older than 70 years (-1.55 nmol/L [-44.7 ng/dL] [CI, -2.05 to -1.06 nmol/L {-59.1 to -30.6 ng/dL}]). Testosterone was inversely associated with body mass index (BMI) (change per SD increase, -2.42 nmol/L [-69.7 ng/dL] [CI, -2.70 to -2.13 nmol/L {-77.8 to -61.4 ng/dL}]). Testosterone concentrations were lower for men who were married (mean difference, -0.57 nmol/L [-16.4 ng/dL] [CI, -0.89 to -0.26 nmol/L {-25.6 to -7.5 ng/dL}]); undertook at most 75 minutes of vigorous physical activity per week (-0.51 nmol/L [-14.7 ng/dL] [CI, -0.90 to -0.13 nmol/L {-25.9 to -3.7 ng/dL}]); were former smokers (-0.34 nmol/L [-9.8 ng/dL] [CI, -0.55 to -0.12 nmol/L {-15.9 to -3.5 ng/dL}]); or had hypertension (-0.53 nmol/L [-15.3 ng/dL] [CI, -0.82 to -0.24 nmol/L {-23.6 to -6.9 ng/dL}]), cardiovascular disease (-0.35 nmol/L [-10.1 ng/dL] [CI, -0.55 to -0.15 nmol/L {-15.9 to -4.3 ng/dL}]), cancer (-1.39 nmol/L [-40.1 ng/dL] [CI, -1.79 to -0.99 nmol/L {-51.6 to -28.5 ng/dL}]), or diabetes (-1.43 nmol/L [-41.2 ng/dL] [CI, -1.65 to -1.22 nmol/L {-47.6 to -35.2 ng/dL}]). Sex hormone-binding globulin was directly associated with age and inversely associated with BMI. Luteinizing hormone was directly associated with age in men older than 70 years. Cross-sectional analysis, heterogeneity between studies and in timing of blood sampling, and imputation for missing data. Multiple factors are associated with variation in male testosterone, SHBG, and LH concentrations. Reduced testosterone and increased LH concentrations may indicate impaired testicular function after age 70 years. Interpretation of individual testosterone measurements should account particularly for age older than 70 years, obesity, diabetes, and cancer. Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668).

Sections du résumé

BACKGROUND
Various factors modulate circulating testosterone in men, affecting interpretation of testosterone measurements.
PURPOSE
To clarify factors associated with variations in sex hormone concentrations.
DATA SOURCES
Systematic literature searches (to July 2019).
STUDY SELECTION
Prospective cohort studies of community-dwelling men with total testosterone measured using mass spectrometry.
DATA EXTRACTION
Individual participant data (IPD) (9 studies;
DATA SYNTHESIS
Two-stage random-effects IPD meta-analyses found a nonlinear association of testosterone with age, with negligible change among men aged 17 to 70 years (change per SD increase about the midpoint, -0.27 nmol/L [-7.8 ng/dL] [CI, -0.71 to 0.18 nmol/L {-20.5 to 5.2 ng/dL}]) and decreasing testosterone levels with age for men older than 70 years (-1.55 nmol/L [-44.7 ng/dL] [CI, -2.05 to -1.06 nmol/L {-59.1 to -30.6 ng/dL}]). Testosterone was inversely associated with body mass index (BMI) (change per SD increase, -2.42 nmol/L [-69.7 ng/dL] [CI, -2.70 to -2.13 nmol/L {-77.8 to -61.4 ng/dL}]). Testosterone concentrations were lower for men who were married (mean difference, -0.57 nmol/L [-16.4 ng/dL] [CI, -0.89 to -0.26 nmol/L {-25.6 to -7.5 ng/dL}]); undertook at most 75 minutes of vigorous physical activity per week (-0.51 nmol/L [-14.7 ng/dL] [CI, -0.90 to -0.13 nmol/L {-25.9 to -3.7 ng/dL}]); were former smokers (-0.34 nmol/L [-9.8 ng/dL] [CI, -0.55 to -0.12 nmol/L {-15.9 to -3.5 ng/dL}]); or had hypertension (-0.53 nmol/L [-15.3 ng/dL] [CI, -0.82 to -0.24 nmol/L {-23.6 to -6.9 ng/dL}]), cardiovascular disease (-0.35 nmol/L [-10.1 ng/dL] [CI, -0.55 to -0.15 nmol/L {-15.9 to -4.3 ng/dL}]), cancer (-1.39 nmol/L [-40.1 ng/dL] [CI, -1.79 to -0.99 nmol/L {-51.6 to -28.5 ng/dL}]), or diabetes (-1.43 nmol/L [-41.2 ng/dL] [CI, -1.65 to -1.22 nmol/L {-47.6 to -35.2 ng/dL}]). Sex hormone-binding globulin was directly associated with age and inversely associated with BMI. Luteinizing hormone was directly associated with age in men older than 70 years.
LIMITATION
Cross-sectional analysis, heterogeneity between studies and in timing of blood sampling, and imputation for missing data.
CONCLUSION
Multiple factors are associated with variation in male testosterone, SHBG, and LH concentrations. Reduced testosterone and increased LH concentrations may indicate impaired testicular function after age 70 years. Interpretation of individual testosterone measurements should account particularly for age older than 70 years, obesity, diabetes, and cancer.
PRIMARY FUNDING SOURCE
Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668).

Identifiants

pubmed: 37639720
doi: 10.7326/M23-0342
doi:

Substances chimiques

Sex Hormone-Binding Globulin 0
Gonadal Steroid Hormones 0
Testosterone 3XMK78S47O
Luteinizing Hormone 9002-67-9

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1221-1234

Subventions

Organisme : Medical Research Council
ID : MC_UU_00004/06
Pays : United Kingdom

Auteurs

Ross J Marriott (RJ)

School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia (R.J.M., K.M.).

Kevin Murray (K)

School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia (R.J.M., K.M.).

Robert J Adams (RJ)

Adelaide Institute for Sleep Health, Flinders University, Bedford Park, South Australia, Australia (R.J.A.).

Leen Antonio (L)

Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium (L.A., D.V.).

Christie M Ballantyne (CM)

Internal Medicine, Baylor College of Medicine, Houston, Texas (C.M.B.).

Douglas C Bauer (DC)

General Internal Medicine, University of California, San Francisco, San Francisco, California (D.C.B.).

Shalender Bhasin (S)

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (S.B.).

Mary L Biggs (ML)

Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (M.L.B.).

Peggy M Cawthon (PM)

San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, California (P.M.C.).

David J Couper (DJ)

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (D.J.C.).

Adrian S Dobs (AS)

School of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, Maryland (A.S.D.).

Leon Flicker (L)

Medical School and Western Australian Centre for Health and Ageing, University of Western Australia, Perth, Western Australia, Australia (L.F.).

David J Handelsman (DJ)

ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia (D.J.H.).

Graeme J Hankey (GJ)

Medical School, University of Western Australia, and Perron Institute for Neurological and Translational Science, Perth, Western Australia, Australia (G.J.H.).

Anke Hannemann (A)

Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, and DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany (A.H.).

Robin Haring (R)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia, and Faculty of Applied Public Health, European University of Applied Sciences, Rostock, Germany (R.H.).

Benjumin Hsu (B)

Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia (B.H.).

Magnus Karlsson (M)

Clinical and Molecular Osteoporosis Research Unit, Departments of Orthopedics and Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden (M.K.).

Sean A Martin (SA)

Australian Institute of Family Studies, Southbank, Victoria, Australia (S.A.M.).

Alvin M Matsumoto (AM)

Department of Medicine, University of Washington School of Medicine, and Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (A.M.M.).

Dan Mellström (D)

Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Göteborg, Sweden (D.M., C.O.).

Claes Ohlsson (C)

Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Göteborg, Sweden (D.M., C.O.).

Terence W O'Neill (TW)

Centre for Epidemiology Versus Arthritis, University of Manchester and National Institute for Health and Care Research Manchester Biomedical Research Centre, Manchester University National Health Service Foundation Trust, Manchester, United Kingdom (T.W.O.).

Eric S Orwoll (ES)

Oregon Health & Science University, Portland, Oregon (E.S.O.).

Matteo Quartagno (M)

Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom (M.Q.).

Molly M Shores (MM)

Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, Washington (M.M.S.).

Antje Steveling (A)

Department of Internal Medicine, University Medicine Greifswald, Greifswald, Germany (A.S.).

Åsa Tivesten (Å)

Wallenberg Laboratory for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, and Department of Endocrinology, Sahlgrenska University Hospital, Region Västra Götaland, Göteborg, Sweden (Å.T.).

Thomas G Travison (TG)

Brigham and Women's Hospital and Institute for Aging Research, Hebrew SeniorLife, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts (T.G.T.).

Dirk Vanderschueren (D)

Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium (L.A., D.V.).

Gary A Wittert (GA)

Freemasons Centre for Male Health & Wellbeing, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia (G.A.W.).

Frederick C W Wu (FCW)

Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences, University of Manchester, Manchester, United Kingdom (F.C.W.W.).

Bu B Yeap (BB)

Medical School, University of Western Australia, and Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Western Australia, Perth, Australia (B.B.Y.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH